Search

everythinglearnresearchcommunity

for

Search:↓

Ritlecitinib improves emotional well-being and activity levels in alopecia areata patients.

Enobosarm may effectively treat androgen receptor-positive breast cancer with fewer side effects.

Ritlecitinib shows promise for treating alopecia areata, especially with early and extended treatment.

Compound 4 is a promising treatment for hair loss with low toxicity.

Targeting amphiregulin may improve treatment for fibrotic diseases and cancer.

The document concludes that ERBB2 mutations are common in extramammary Paget disease and may respond to systemic treatments like cancer immunotherapy.

Erlotinib may cause scarring hair loss.

Tofacitinib may effectively treat skin symptoms in difficult cases of dermatomyositis.

Adding a second method to PROTACs could improve cancer treatment.

Ritlecitinib is effective long-term for treating alopecia areata in teens.

A cancer drug caused unusual hair growth on a 100-year-old man's scalp and eyelashes.

Vorasidenib can cause unusual hair growth.

Ritlecitinib effectively improves hair regrowth and physician satisfaction in severe alopecia areata over time.

Long-term use of 5α-reductase inhibitors may improve survival in men with kidney cancer.

Ritlecitinib improved hair regrowth and emotional well-being in some alopecia areata patients.

Loss of the p53 gene alone causes tumors, and losing both p53 and Rb genes speeds up aggressive skin cancer.

Antizyme slows skin tumor growth by reducing cell growth in mice.

Ritlecitinib effectively treats alopecia areata with manageable side effects.

Continued ritlecitinib treatment helps sustain hair regrowth in alopecia areata patients.

Suppressing ODC activity reduces tumor growth in hair follicles.

Ponatinib can cause a rare skin reaction that resolves with topical treatment and temporary drug discontinuation.

New treatments targeting the Hedgehog pathway can help treat advanced skin cancer but may have side effects and their effectiveness in early stages is unknown.

Stopping gefitinib improved scalp condition in a woman with lung cancer.

The protein ER71/ETV2 helps regrow hair after chemotherapy by improving the growth of new blood vessels.

A PTH-based treatment improved hair regrowth better than ruxolitinib in a mouse model of hair loss.

A man developed skin issues from cancer medication, which improved with specific treatments.

An 84-year-old man developed a rare scalp condition from a cancer drug but continued treatment as it was otherwise well tolerated.